secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0000950170-23-067461
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA collaborates with Gilead for Phase 1 combo of IDE397 + Trodelvy in MTAP-deletion bladder cancer
--------------------------------------------------------------------------------

- IDEAYA and Gilead will evaluate IDE397 (MAT2A inhibitor) plus Trodelvy (Trop-2 ADC) in MTAP-deletion bladder cancer.
- MTAP-deletion prevalence in bladder cancer is ~26%, with no approved therapies for this population.
- IDEAYA sponsors the Phase 1 trial; Gilead provides Trodelvy at no cost; each party retains commercial rights to its own compound.
- IDEAYA is also evaluating IDE397 in an ongoing Phase 1/2 monotherapy and in a separate Amgen combination study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023067461/0000950170-23-067461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017023067461/idya-20231129.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-067461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer